NT157, 一种选择性IRS-1/2抑制剂，具有在癌细胞以及肿瘤微环境中的基质细胞中抑制IGF-1R和STAT3信号通路的潜力，因而减少癌细胞的生存率。 Information NT157 NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate) , has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. Targets IRS1/2 In vitro NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro. These effects were correlated with decreased proliferation and increasing apoptosis of LNCaP cells and increasing G2-M arrest in PC3 cells. NT157 can mediate suppression of IGF1R-mediated survival signaling through the established mechanism for negative feedback of IGF1R signaling: targeting IRS1/2 for serine phosphorylation and subsequent degradation. NT157 displayed little to no effect on the survival of normal melanocytes and fibroblasts. In vivo NT157 suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel. Melanoma tumor growth and metastasis is efficiently inhibited by NT157. Cell Research(from reference) Cell lines：LNCaP cells, PC3 cells Concentrations：0-10 μM Incubation Time：72 h